ALK Abello to Showcase Nasal Adrenaline Data and 20-Year SLIT-Tablet Insights at EAACI 2026
Event summary
- ALK Abello will present data on real-world use of nasal adrenaline and 20 years of SLIT-tablet experience at EAACI 2026 in Istanbul from June 12-15, 2026.
- Two symposia will focus on anaphylaxis management and allergy immunotherapy insights.
- ALK has contributed 29 abstracts to the scientific program, including clinical trial findings on allergic rhinitis and rhinoconjunctivitis.
- Key presentations include patient preferences for nasal adrenaline vs. auto-injectors and long-term effectiveness of SLIT-tablets.
The big picture
ALK Abello's presentation at EAACI 2026 underscores the growing importance of real-world evidence in allergy treatment validation. The company's focus on nasal adrenaline and SLIT-tablets aligns with industry trends toward more accessible and preventative allergy therapies. With 29 abstracts in the conference program, ALK is positioning itself as a leader in allergy immunotherapy innovation, potentially expanding its market reach in both pediatric and adult allergy segments.
What we're watching
- Therapeutic Shift
- How nasal adrenaline adoption will affect anaphylaxis management market share versus traditional auto-injectors.
- Regulatory Pathways
- Whether ALK's SLIT-tablet data will accelerate approvals for new allergy immunotherapy applications.
- Market Expansion
- The pace at which ALK can commercialize its peanut SLIT-tablet following phase I/II trial results.
Related topics